Logo image
Back
Exploiting the tumor phenotype using biodegradable submicron carriers of chemotherapeutic drugs
Journal article   Peer reviewed

Exploiting the tumor phenotype using biodegradable submicron carriers of chemotherapeutic drugs

Sean M Geary and Aliasger K Salem
Critical reviews in oncogenesis, Vol.19(3-4), pp.269-280
2014
DOI: 10.1615/CritRevOncog.2014011518
PMCID: PMC4183966
PMID: 25271435
url
https://www.ncbi.nlm.nih.gov/pmc/articles/4183966View
Open Access

Abstract

Tumor tissues possess characteristics that distinguish them from healthy tissues and make them attractive targets for submicron carriers of chemotherapeutic drugs (CTX). CTX are generally administered systemically in free form to cancer patients resulting in unwanted cytotoxic effects and placing limitations on the deliverable CTX dose. In an effort to raise the therapeutic index of CTX there are now liposome-based CTX formulations in clinical use that are more tumor specific than the free form of CTX. However, progression to liposome-based chemotherapy in the clinic has been slow and there have been no approved formulations introduced in the last decade. Alternative carrier systems such as those made from the biodegradable polymer poly(lactic-co-glycolic) acid (PLGA) have been investigated in preclinical settings with promising outcomes. Here we review the principle behind biodegradable submicron carriers as CTX delivery vehicles for solid tumors with a specific focUS on liposomes and PLGA-based carriers, highlighting the strengths and weaknesses of each system.
 Antineoplastic Agents - administration & dosage Drug Carriers - chemistry Drug Carriers - metabolism Humans Lactic Acid - administration & dosage Liposomes Phenotype Polyglycolic Acid - administration & dosage

Details

Metrics

27 Record Views
Logo image